Nanofàrmacs

治疗局部及远端肿瘤的方法

Resumen de: WO2025024674A2

The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprising the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.

METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES

Resumen de: AU2024356983A1

The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol%; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol% and 65 mol%; and an ionizable cationic amino lipid present at a content of between 15 mol% and 45 mol%; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol% content is relative to total lipid present in the lipid nanoparticle.

HAEMATOPOIETIC STEM AND/OR PROGENITOR CELL DELIVERY METHOD AND COMPOSITIONS FOR USE THEREOF

Resumen de: AU2024354577A1

The present disclosure provides a method for delivery of cargo to a haematopoietic stem or progenitor cell of a subject, the method comprising contacting a lipid nanoparticle encapsulating the cargo with the haematopoietic stem or progenitor cell ex vivo or in vivo, thereby causing cellular uptake of the cargo, the lipid nanoparticle having between 30 mol% and 70 mol% of a neutral or zwitterionic amphipathic lipid having a net-neutral charge at physiological pH, an ionizable cationic lipid, and a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5. Further provided are lipid nanoparticle compositions and uses thereof.

VACCINE DELIVERY METHOD AND COMPOSITION FOR USE THEREOF

Resumen de: AU2024356921A1

Provided is a method for inducing an immune response in a subject to treat or prevent a disease or disorder, the method comprising administering a vaccine comprising a lipid nanoparticle encapsulating nucleic acid encoding an antigenic protein, peptide or fragment thereof, a neutral lipid content of from 30 mol% to 70 mol%, a sterol or derivative thereof and an ionizable cationic amino lipid at between 5 and 50 mol%, and a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0 mol% to 5 mol%, wherein the administering of the lipid nanoparticle results in the immune response against the antigenic protein, peptide or fragment thereof expressed by the mRNA in the subject, wherein each mol% is measured relative to a total lipid content of the lipid nanoparticle. The disclosure further provides vaccine compositions and use of such compositions to induce an immune response in a subject.

NANOFIBROUS DERMAL MAT, TRANSDERMAL PATCHES, DRESSINGS AND DERMATOLOGICAL PRODUCTS INCLUDING SAME

Resumen de: AU2024348602A1

A nanofibrous dermal mat comprising: electrospun nanofibers formed from an electrospinning mixture of polyvinyl alcohol (PVA) and at least one polyglycol; and at least one active pharmaceutical ingredient (API) dispersed throughout said electrospun nanofibers.

TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF

Resumen de: AU2024346186A1

The present invention relates to a topical nano-dispersion composition comprising one or more non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, local anesthetics, analgesics, gabapentinoids, alone or combinations thereof. The composition includes a dispersed phase containing drug(s), lipids, surfactants, amphiphilic penetration enhancers, and solvents, along with an aqueous phase. The nano-dispersion has particle sizes below 300 nm with unimodal particle size distribution, offering enhanced skin permeability and controlled drug release for up to 24 hours. The composition can be formulated into gels, creams, patches, lotions, liquid, or sprays, providing improved patient compliance through non-greasy, fast-absorbing formulations with extended shelf life.

THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S)

Resumen de: US20260124210A1

Disclosed herein are therapeutic constructs including a delivery particle, at least one anti-cancer agent (e.g., a mitotic kinase inhibitor), and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION

Resumen de: US20260125680A1

Therapeutic compositions and methods for treating cancer, e.g., pancreatic cancer, that use nanoparticles linked to inhibitory nucleic acids, e.g., siRNAs, targeting an immune checkpoint molecule, e.g., programmed cell death 1 ligand 1 (PD-L1).

NUCLEIC ACID-CONTAINING LIPID NANO-PARTICLE AND USE THEREOF

Resumen de: US20260124306A1

0000 The present invention provides a lipid nanoparticle containing the following (a) to (c): (a) a nucleic acid encoding a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR); (b) a cationic lipid; and (c) a non-cationic lipid. The present invention also provides a CAR- or exogenous TCR-expressing immunocyte obtained by introducing the lipid nanoparticle into in vivo or ex vivo T cells, and an in vivo or ex vivo therapeutic approach using the immunocytes for disease such as cancer and the like.

USE OF NOVEL NANO-FORMULATION CONTAINING GINGERENONE A IN PREPARATION OF ANTI-TUMOR DRUG

Resumen de: WO2026091179A1

Disclosed in the present invention is a use of a novel nano-formulation containing gingerenone A in the preparation of an anti-tumor drug. The nano-formulation comprises aminated dendritic mesoporous silica and gingerenone A loaded on the aminated dendritic mesoporous silica.

Methods of Producing Cobalt Nanoparticles and Hollow Metal Nanospheres

Resumen de: US20260124304A1

0000 Provided are methods of producing cobalt-based nanoparticles (CoBNPs) of a pre-selected diameter. The methods include reducing Co<2+> ions with a sodium borohydride (NaBH<4>) solution having a selected ratio of tetrahydroxyborate (B(OH)<4>− ) to tetrahydroborate (BH<4>− ) based on the pre-selected diameter, where the ratio of B(OH)<4>− to BH<4>− is positively correlated with the pre-selected diameter. Also provided are methods of using the CoBNPs to produce hollow metal nanospheres (HMNs). Methods of producing CoBNP core/metal shell structures are also provided, such methods including combining in an anaerobic galvanic exchange reaction a deaerated solution including CoBNP scaffolds and a deaerated solution including a metal. Also provided are methods of producing HMNs from the CoBNP core/metal shell structures. Compositions and kits that find use in practicing the methods of the present disclosure and using HMNs produced in accordance with the methods of the present disclosure, are also provided.

Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency

Resumen de: US20260125677A1

0000 Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of α1-antitrypsin (AAT), such as seen in subjects having α1-antitrypsin deficiency (AATD), are provided.

METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS

Resumen de: US20260124189A1

0000 Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

Silver nanoplate compositions and methods

Resumen de: AU2026203055A1

SILVER NANOPLATE COMPOSITIONS AND METHODS Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. pr p r

MELATONIN RECEPTOR AGONIST COMPLEX, TRANSDERMAL DRUG DELIVERY SYSTEM, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026092457A1

A melatonin receptor agonist complex, a transdermal drug delivery system, and a preparation method therefor and the use thereof. The complex comprises a polymer pressure-sensitive adhesive, a melatonin receptor agonist dispersed and miscible in the polymer pressure-sensitive adhesive, a penetration enhancer, and polyvinylpyrrolidone, wherein the polyvinylpyrrolidone is present in the polymer pressure-sensitive adhesive in the form of a dendritic nanoframework structure, and the melatonin receptor agonist and the penetration enhancer are adsorbed around the dendritic nanoframework structure. Compared with the prior art, the dendritic nanostructure can improve the transdermal delivery efficiency of the melatonin receptor agonist.

Comprehensive Cannabinoid Compositions and Methods for the Management of Anxiety Disorders

Resumen de: US20260124218A1

0000 This disclosure introduces an advanced cannabinoid-based nanoplatform formulation for oral drop administration, designed for fast-acting anxiety control via the sublingual route to maximize bioavailability. The formulation incorporates broad-spectrum CBD, including cannabinoids such as CBD, CBG, and CBC, alongside terpenes, flavonoids, selected herbal extracts, and essential vitamins to enhance therapeutic efficacy. This formulation targets multiple therapeutic endpoints relevant to a range of anxiety disorders, including Panic Disorder, Specific Phobias, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD), and others. Symptoms addressed span from restlessness, nervousness, and fatigue to concentration difficulties, irritability, muscle tension, sleep disturbances, palpitations, excessive sweating, tremors, nausea, and gastrointestinal discomfort. The active compounds act centrally by modulating 5HT1-A serotonin receptors, dopaminergic pathways, and CB1 and CB2 cannabinoid receptors, aiming to reduce neuroinflammation and rebalance neurotransmitters. Together, cannabinoids, herbal extracts, and vitamins synergistically reduce oxidative stress, fostering mental well-being and delivering a comprehensive approach to anxiety management.

METHOD OF PRODUCING ENGINEERED EXOSOME-MIMETIC VESICLES

Resumen de: US20260124152A1

0000 A method for producing one or more engineered exosome-mimetic vesicles for targeted drug delivery, including, engineering one or more eukaryotic cells to stably express a Chimeric Antigen Receptor (CAR) protein on their surface; incubating the one or more engineered eukaryotic cells with a therapeutic cargo; and subjecting the one or more incubated cells to a mechanical extrusion process to form nanoscale one or more engineered exosome-mimetic vesicle with the CAR protein displayed on their surface and the therapeutic cargo encapsulated within.

LIPID NANOPARTICLE LYOPHILIZED COMPOSITION

Resumen de: US20260124154A1

0000 A lyophilized composition capable of encapsulating any nucleic acid with high efficiency and easily is provided. A lyophilized composition of lipid nanoparticles not containing a nucleic acid but containing an ionic lipid, a sterol, a PEG lipid, an acidic buffer component that shows a buffering action at pH 1-6, and a cryoprotectant, wherein a weight ratio of the cryoprotectant and a total lipid is 10:1-1000:1.

PHARMACEUTICAL FORMULATIONS OF CURCUMIN AND/OR RESVERATROL COMPOUNDS

Resumen de: US20260124160A1

0000 A pharmaceutical composition comprising: (a) a resveratrol compound such as resveratrol, a curcumin compound such as curcumin, or a combination thereof; (b) an osmolality adjusting agent, and (c) a non-ionic surfactant, the pharmaceutical composition having an osmolality value ranging from 300±70 mOsm/kg. Also provided herein are therapeutic applications for the pharmaceutical compositions provided herein.

PLANT-DERIVED EXTRACELLULAR VESICLE (EVS) COMPOSITIONS AND USES THEREOF

Resumen de: US20260124156A1

0000 The invention relates to a composition comprising a population of plant-derived extracellular vesicles (EVs) having a diameter ranging from 10 to 500 nm and showing pro-angiogenic, and anti-bacterial activity, for use in therapeutic applications. The invention also relates to a method of loading one or more negatively-charged biologically-active molecules into said population of EVs.

USE OF LIPID NANOPARTICLES AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER

Resumen de: US20260124295A1

Disclosed are methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI). The methods comprise administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein, and administering an ICI to the subject, where the composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI. In some aspects, the methods comprising administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens, and administering an ICI to the subject where the composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI.

USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS

Resumen de: US20260124224A1

Provided is a use of a combined composition in preparing a drug for resisting fungal and bacterial infections. Active components of the combined composition are an antibiotic and an antibiotic adjuvant, wherein the antibiotic adjuvant is celastrol or a pharmaceutical salt thereof. The present application creatively discovers that celastrol or the pharmaceutical salt thereof can be combined with the antibiotic and the combination has a very excellent effect in resisting the fungal and bacterial infections, especially in resisting the fungal infections. Celastrol or the pharmaceutical salt thereof can enhance an antimicrobial effect of the antibiotic, especially an antifungal effect of the antibiotic, significantly increasing an antimicrobial sensitivity of the antibiotic and inhibiting the occurrence of fungal or bacterial drug-resistance. As an antibiotic adjuvant-antibiotic drug platform, the combined composition provides a new strategy for achieving an efficient antimicrobial effect, and the application dosage forms and the application scenarios are very diverse.

PROCESS AND APPARATUS FOR ENCAPSULATION OF HYDROPHOBIC MOLECULES

Resumen de: WO2026090761A1

The present document describes an apparatus for the encapsulation of a hydrophobic molecule into a capsule formed from biological molecules from a bulk multicellular biological material, and a process for extracting and encapsulating biological molecules from a bulk multicellular biological material.

APPLICATION OF DHA@ZIF-8 IN TREATMENT OF EXPERIMENTAL CEREBRAL MALARIA

Resumen de: US20260124307A1

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of DHA@ZIF-8 in the treatment of experimental cerebral malaria. In the disclosure, an experimental cerebral malaria model is first established. Subsequently, DHA@ZIF-8 is used for treatment in the model, and the therapeutic efficacy of the nanodrug against experimental cerebral malaria is evaluated using behavioral, pathological, and molecular biological techniques. In the disclosure, the use of ZIF-8 as a carrier achieves the effect of slowly releasing the drug, prolonging the duration of action of the drug in vivo, so as to more effectively kill Plasmodium. Compared with natural administration, this approach extends the duration of action of DHA.

PREPARATION METHOD AND APPLICATION OF TARGETED INTRACELLULAR NANOVESICLE

Nº publicación: AU2024353189A1 07/05/2026

Solicitante:

GOODWILL MEDICAL ENGINEERING TECHNOLOGY TIANJIN CO LTD
GOODWILL MEDICAL ENGINEERING TECHNOLOGY (TIANJIN) CO., LTD.

Resumen de: AU2024353189A1

A preparation method and application of a targeted intracellular nanovesicle. The intracellular nanovesicle has a large yield, a small particle size and a narrow particle size distribution range, has higher encapsulation efficiency and drug loading efficiency when used as a carrier to load a drug, and has a wider distribution range and degree in a mode of intravitreal injection, for example, the drug loaded in the mode of intravitreal injection can be absorbed more quickly, and the intracellular nanovesicle has extremely good application and research value in the field of medicine. Particularly, targeting performance is given to the intracellular nanovesicle, and a targeting peptide is carried in the intracellular nanovesicle by modifying Lamp2b to obtain the intracellular nanovesicle having the targeting performance. The nanovesicle has a large yield and high targeting performance, can exert a therapeutic effect or a drug carrier effect more efficiently, and has an extremely good application prospect and research value.